
    
      This is a Phase I study, to evaluate the safety, tolerability, pharmacokinetics and
      anti-tumor activity of AST2818 in patients with advanced non-small cell lung cancer who
      progressed on prior therapy with an epidermal growth factor receptor tyrosine kinase
      inhibitor agent. The tolerability of AST2818 20 mg/day - 240 mg/day in 14 subjects was
      observed. 7-days observation period for a single dose and 21-days observation period for
      multiple doses.
    
  